All Stories

  1. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells

    Article • PLoS ONE, June 2020, PLOS

    stephanie Filleur

  2. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity

    Article • The Prostate, May 2018, Wiley

    stephanie Filleur

  3. PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro

    Article • PLoS ONE, April 2017, PLOS

    stephanie Filleur

  4. Modes of action of low-dose cabazitaxel in combination with the antiangiogenic and antitumoral pigment epithelium-derived factor in prostate cancer.

    Article • Journal of Clinical Oncology, February 2017, American Society of Clinical Oncology (ASCO)

    stephanie Filleur

  5. Assessment of phagocytic activity in live macrophages-tumor cells co-cultures by Confocal and Nomarski Microscopy

    Article • Biology Methods and Protocols, January 2017, Oxford University Press (OUP)

    stephanie Filleur

  6. Abstract 288: Low-dose cabazitaxel inhibits the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with greater efficacy than docetaxel

    Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

    stephanie Filleur

  7. Abstract 3359: PEDF modulatory action on macrophages: A new way to curb prostate cancer development

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    stephanie Filleur

  8. MP66-04 CABAZITAXEL INHIBITS THE PROLIFERATION OF HUMAN CASTRATION-REFRACTORY PROSTATE CANCER CELLS IN VITRO AND ENHANCES THE ANTI-TUMOR PROPERTIES OF THE ANGIO-INHIBITORY PIGMENT EPITHELIUM-DERIVED FACTOR IN VIVO WITH A GREATER EFFICACY THAN DOCETAXEL

    Article • The Journal of Urology, April 2015, Elsevier

    stephanie Filleur

  9. Effect of cabazitaxel on the growth of human castration-refractory prostate cancer cells in vitro compared to docetaxel and on the anti-tumor properties of the angio-inhibitor PEDF in vivo.

    Article • Journal of Clinical Oncology, March 2015, American Society of Clinical Oncology (ASCO)

    stephanie Filleur

  10. MP25-06 ASSESSMENT OF INDUCTION OF CALCIUM OXALATE NEPHROLITHIASIS IN A NOVEL PORCINE STONE FORMING MODEL - PILOT STUDY -

    Article • The Journal of Urology, April 2014, Elsevier

    stephanie Filleur

  11. Abstract 5097: PEDF inhibits bone metastases formation, prolongs survival and enhances the antitumor efficacy of low-dose chemotherapy in castration-refractory prostate cancer.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    stephanie Filleur

  12. 793 PIGMENT EPITHELIUM-DERIVED FACTOR INHIBITS BONE METASTASES FORMATION, PROLONGS SURVIVAL AND ENHANCES THE IN VIVO ANTITUMOR ACTIVITIES OF LOW-DOSE CHEMOTHERAPY IN CASTRATION-REFRACTORY PROSTATE CANCER

    Article • The Journal of Urology, April 2013, Elsevier

    stephanie Filleur

  13. Effect of PEDF on the in vivo antitumor activities of low-dose chemotherapy in CRPC.

    Article • Journal of Clinical Oncology, February 2013, American Society of Clinical Oncology (ASCO)

    stephanie Filleur

  14. The Clinical Usefulness of Nuclear Matrix Protein-22 in Patients with End-Stage Renal Disease and Microscopic Hematuria

    Article • Renal Failure, November 2012, Informa Healthcare

    stephanie Filleur

  15. Positive correlation between PEDF expression levels and macrophage density in the human prostate

    Article • The Prostate, October 2012, Wiley

    stephanie Filleur

  16. AFM nano-mechanics and calcium dynamics of prostate cancer cells with distinct metastatic potential

    Article • Biochimica et Biophysica Acta (BBA) - General Subjects, July 2012, Elsevier

    stephanie Filleur

  17. Abstract 3717: Pigment epithelium-derived factor prolongs survival and enhances thein vivoantitumor activities of low-dose chemotherapy in castration-refractory prostate cancer

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    stephanie Filleur

  18. 780 PIGMENT EPITHELIUM-DERIVED FACTOR PROLONGS SURVIVAL AND ENHANCES THE IN VIVO ANTI-TUMOR ACTIVITIES OF LOW-DOSE CHEMOTHERAPY IN CASTRATION-REFRACTORY PROSTATE CANCER

    Article • The Journal of Urology, April 2012, Elsevier

    stephanie Filleur

  19. Effect of PEDF on survival and the in vivo antitumor activities of low-dose chemotherapy in castration-refractory prostate cancer.

    Article • Journal of Clinical Oncology, February 2012, American Society of Clinical Oncology (ASCO)

    stephanie Filleur

  20. Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer – Review of the literature

    Article • Cancer Treatment Reviews, October 2011, Elsevier

    stephanie Filleur

  21. Asymptomatic Bacteriuria: Significance for Different Patient Population

    Article • September 2011, IntechOpen

    stephanie Filleur

  22. PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ

    Article • Cytokine, August 2011, Elsevier

    stephanie Filleur

  23. Extraluminal Colonic Carcinoma Invading into Kidney: A Case Report and Review of the Literature

    Article • ISRN Urology, January 2011, Hindawi Publishing Corporation

    stephanie Filleur

  24. Abstract 3959: Pigment epithelium-derived factor blocks Interleukin-8 mediated proliferation in prostate cancer cells through PEDF-R/PLA2 receptor and regulation of the nuclear factor-κB and peroxisome proliferator activated receptor γ

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    stephanie Filleur

  25. 1297 INTEGRATOR COMPLEX SUBUNIT 6/DELETED IN CANCER 1 INHIBITS GROWTH OF HUMAN ANDROGEN-INDEPENDENT PROSTATE CANCER CELLS BY ALTERING THE CELL CYCLE PROFILE AND WNT SIGNALING

    Article • The Journal of Urology, April 2010, Elsevier

    stephanie Filleur

  26. PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy

    Article • The Prostate, December 2009, Wiley

    stephanie Filleur

  27. Die Strangulationsverletzung des Penis

    Article • Aktuelle Urologie, November 2009, Thieme Publishing Group

    stephanie Filleur

  28. Leiomyosarcoma of the urinary bladder presenting as life threatening gross hematuria

    Article • Cancer Immunology Immunotherapy, June 2009, Springer Science + Business Media

    stephanie Filleur

  29. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy

    Article • Cancer Immunology Immunotherapy, April 2009, Springer Science + Business Media

    stephanie Filleur

  30. Characterization of PEDF: A multi-functional serpin family protein

    Article • Journal of Cellular Biochemistry, April 2009, Wiley

    stephanie Filleur

  31. INTS6/DICE1 inhibits growth of human androgen-independent prostate cancer cells by altering the cell cycle profile and Wnt signaling

    Article • Cancer Cell International, January 2009, Springer Science + Business Media

    stephanie Filleur

  32. Pigment Epithelium-Derived Factor and Interleukin-6 Control Prostate Neuroendocrine Differentiation via Feed-Forward Mechanism

    Article • The Journal of Urology, June 2008, Elsevier

    stephanie Filleur

  33. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma

    Article • BJU International, July 2007, Wiley

    stephanie Filleur

  34. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy

    Article • International Urology and Nephrology, June 2007, Springer Science + Business Media

    stephanie Filleur

  35. 434 TWO FUNCTIONAL EPITOPES OF PEDF BLOCK ANGIOGENESIS AND INDUCE DIFFERENTIATION IN PROSTATE CANCER

    Article • European Urology Supplements, March 2007, Elsevier

    stephanie Filleur

  36. 99 DELETED IN CANCER 1 (DICE1): SEARCH FOR A FUNCTION IN PROSTATE CARCINOMA (PCA)

    Article • European Urology Supplements, March 2007, Elsevier

    stephanie Filleur

  37. Androgen receptor targets NFκB and TSP1 to suppress prostate tumor growthin vivo

    Article • International Journal of Cancer, January 2007, Wiley

    stephanie Filleur

  38. 112 POSTER Pigment Epithelial-Derived Factor: Development of anti-angiogenic peptides

    Article • European Journal of Cancer Supplements, November 2006, Elsevier

    stephanie Filleur

  39. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer

    Article • BJU International, September 2006, Wiley

    stephanie Filleur

  40. Die idiopathische retroperitoneale Fibrose (Morbus Ormond)

    Article • Aktuelle Urologie, July 2006, Thieme Publishing Group

    stephanie Filleur

  41. THERAPEUTIC PROSPECTS FOR PEDF AND ITS PEPTIDES IN NERVE REGENERATION ON CULTURED MAJOR PELVIC AND SPINAL CORD GANGLIA

    Article • European Urology Supplements, April 2006, Elsevier

    stephanie Filleur

  42. Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer

    Article • Oncology Research and Treatment, October 2005, Karger Publishers

    stephanie Filleur

  43. Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer

    Article • Cancer Research, June 2005, American Association for Cancer Research (AACR)

    stephanie Filleur

  44. Laparoscopic (endoscopic) radical prostatectomy: techniques and results

    Article • April 2005, SPIE

    stephanie Filleur

  45. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1in vivo

    Article • International Journal of Cancer, January 2005, Wiley

    stephanie Filleur

  46. Nuclear Factor of Activated T Cells Balances Angiogenesis Activation and Inhibition

    Article • The Journal of Experimental Medicine, June 2004, Rockefeller University Press

    stephanie Filleur

  47. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects

    Article • Genes & Development, June 2001, Cold Spring Harbor Laboratory Press

    stephanie Filleur

  48. CBP/p300 histone acetyl-transferase activity is important for the G1/S transition

    Article • Oncogene, May 2000, Nature

    stephanie Filleur

  49. The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun

    Article • Oncogene, May 1999, Springer Science + Business Media

    Dr Bernard Binetruy, stephanie Filleur